The regulatory consequences of last year’s discovery that carcinogenic impurities called nitrosamines tainted a major supplier’s active ingredient for a popular blood pressure medication are becoming clear.
There will be greater scrutiny, more testing and tighter limits not only for that medication, valsartan, but also for other similar blood pressure medications – and
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?